REGN - Regeneron Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
312.55
-7.71 (-2.41%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close320.26
Open318.76
Bid306.03 x 800
Ask318.54 x 900
Day's Range311.36 - 320.28
52 Week Range295.27 - 442.00
Volume584,356
Avg. Volume854,214
Market Cap34.12B
Beta (3Y Monthly)1.05
PE Ratio (TTM)14.80
EPS (TTM)21.11
Earnings DateJul 31, 2019 - Aug 5, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est392.00
Trade prices are not sourced from all markets
  • Ocular (OCUL) Gets FDA Nod for Label Expansion of Dextenza
    Zacks22 hours ago

    Ocular (OCUL) Gets FDA Nod for Label Expansion of Dextenza

    Ocular (OCUL) clinches the FDA approval for the label expansion of Dextenza to treat ocular inflammation following ophthalmic surgery.

  • This would be the worst-case scenario for health stocks, according to UBS
    MarketWatch3 days ago

    This would be the worst-case scenario for health stocks, according to UBS

    Health-care reform is coming, UBS analysts say, and it could have severe consequences for health companies.

  • Regeneron And Sanofi Tried To Outperform Themselves — And Couldn't
    Investor's Business Daily4 days ago

    Regeneron And Sanofi Tried To Outperform Themselves — And Couldn't

    AnaptysBio stock tumbled Friday after the results of a study from Regeneron Pharmaceuticals and Sanofi cast doubt on the biotech company's ability to compete in asthma treatment.

  • Here's Why AnaptysBio Shares Are Sliding Today
    Motley Fool4 days ago

    Here's Why AnaptysBio Shares Are Sliding Today

    A potential competitor stumbled in a midstage asthma trial.

  • Sanofi/Regeneron's Asthma Candidate Meets Goal in Study
    Zacks4 days ago

    Sanofi/Regeneron's Asthma Candidate Meets Goal in Study

    Sanofi/Regeneron's IL-33 antibody REGN3500 meets primary endpoint in phase II study in asthma. It does not show increased benefit compared to Dupixent.

  • Benzinga4 days ago

    The Daily Biotech Pulse: ContraVir's Volatile Ride Continues, Late-Stage Disappointment For Exelixis, Regeneron-Sanofi Breathe Easy

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 20) Abbott Laboratories (NYSE: ABT ) ANI Pharmaceuticals ...

  • PR Newswire4 days ago

    Regeneron and Sanofi Announce Positive Topline Phase 2 Results for IL-33 Antibody in Asthma

    Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a Phase 2 proof-of-concept trial evaluating the investigational IL-33 antibody REGN3500 (SAR440340) met the primary endpoint of improvement in loss of asthma control when comparing REGN3500 monotherapy to placebo. Patients treated with Dupixent® (dupilumab) monotherapy did numerically better than REGN3500 across all endpoints, although the trial was not powered to show differences between active treatment arms. The combination of REGN3500 and Dupixent also did not demonstrate increased benefit compared to Dupixent monotherapy in this trial.

  • The Zacks Analyst Blog Highlights: Amgen, Alexion, Regeneron, Allergan and Savara
    Zacks5 days ago

    The Zacks Analyst Blog Highlights: Amgen, Alexion, Regeneron, Allergan and Savara

    The Zacks Analyst Blog Highlights: Amgen, Alexion, Regeneron, Allergan and Savara

  • Implied Volatility Surging for Regeneron (REGN) Stock Options
    Zacks5 days ago

    Implied Volatility Surging for Regeneron (REGN) Stock Options

    Investors need to pay close attention to Regeneron (REGN) stock based on the movements in the options market lately.

  • Biotech Stock Roundup: Amgen Gets FDA Nod for Kanjinti, Regeneron Presents Data
    Zacks6 days ago

    Biotech Stock Roundup: Amgen Gets FDA Nod for Kanjinti, Regeneron Presents Data

    Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.

  • Alnylam Completes Enrollment in Phase III Study of Lumasiran
    Zacks7 days ago

    Alnylam Completes Enrollment in Phase III Study of Lumasiran

    Alnylam (ALNY) completes enrollment in its ILLUMINATE-A phase III study on lumasiran for the treatment of adults and children with primary hyperoxaluria type 1.

  • Barrons.com7 days ago

    Regeneron Stock Faces More Uncertainty as Rivals Gear Up, Analyst Says

    Most of the biotech’s revenue comes from a single blockbuster drug, called Eylea. And Eylea is under siege.

  • Markit7 days ago

    See what the IHS Markit Score report has to say about Regeneron Pharmaceuticals Inc.

    Regeneron Pharmaceuticals Inc NASDAQ/NGS:REGNView full report here! Summary * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for REGN with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting REGN. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold REGN had net inflows of $1.82 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Reuters7 days ago

    CORRECTED-UPDATE 1-Uganda clears three experimental Ebola treatments, watches for spread

    Health workers have got the all-clear to use three experimental Ebola treatments in Uganda, a week after the deadly disease spread over the border from Democratic Republic of Congo, authorities said on Tuesday. Two people who had travelled from Congo died in Uganda last week, the World Health Organization said. A three-year-old boy who was sent back to Congo after testing positive for the disease died at the weekend, Congo's health ministry said.

  • Regeneron (REGN) Presents Positive Data on Lymphoma Candidate
    Zacks8 days ago

    Regeneron (REGN) Presents Positive Data on Lymphoma Candidate

    Regeneron (REGN) reports positive early-stage data on REGN1979 in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma.

  • TheStreet.com9 days ago

    2 Well-Known Stocks You Should Consider Shorting This Week

    Using recent actions and grades from TheStreet's Quant Ratings and layering on technical analysis of the charts of those stocks, Trifecta Stocks identifies five names each Friday that look bearish. While we will not be weighing in with fundamental analysis we hope this piece will give investors interested in stocks on the way down a good starting point to do further homework on the names. recently was downgraded to Hold with a C+ rating by TheStreet's Quant Ratings.

  • Here’s What Hedge Funds Think About Regeneron Pharmaceuticals Inc (REGN)
    Insider Monkey11 days ago

    Here’s What Hedge Funds Think About Regeneron Pharmaceuticals Inc (REGN)

    Reputable billionaire investors such as Jim Simons, Cliff Asness and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required to invest in a hedge fund and most successful hedge funds won't accept your savings unless you commit at least $5 million) by pinpointing […]

  • PR Newswire11 days ago

    Regeneron CD20xCD3 Bispecific REGN1979 Shows Positive Results in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma, including in CAR-T Failures

    Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive early-stage data for REGN1979 in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). The emerging data, which includes patients with R/R diffuse large B-cell lymphoma (DLBCL) who had progressed after CAR-T therapy, will be presented tomorrow at the 24th Congress of the European Hematology Association (EHA). "We are very encouraged by the continued high response rates observed with REGN1979 in both relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma, cancers with typically poor outcomes," said Israel Lowy, M.D., Ph.D., Senior Vice President and Head of Clinical and Translational Sciences, Oncology at Regeneron.

  • Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Insiders Have Been Selling
    Simply Wall St.13 days ago

    Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Insiders Have Been Selling

    It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...

  • Barrons.com14 days ago

    The Regeneron Stock Selloff Is Driven by Fear, Not Substance, Analyst Says

    Regeneron (ticker: REGN) markets drugs for a range of conditions, including rheumatoid arthritis and various forms of cancer, and shares have struggled since last fall. Regeneron stock is among the worst-performing of the large biotech companies. In May, the company announced earnings that fell short of analyst expectations, as Barron’s reported.

  • Here's Why Regeneron Pharmaceuticals Tumbled 12% in May
    Motley Fool15 days ago

    Here's Why Regeneron Pharmaceuticals Tumbled 12% in May

    Sales growth is slowing, and there's an issue with one of the biotech's pipeline drugs.

  • MoneyShow15 days ago

    Regeneron- A Rich Research Pipeline

    Regeneron Pharmaceuticals (REGN) recently had a rough earnings release; the biotech firm reported first-quarter revenue of $1.71 billion, a 13% year-over-year jump but about $50 million lower than analysts' expectation, asserts Scott Chan, editor of The Complete Investor.

  • Benzinga17 days ago

    The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts

    Biotech stocks staged a steady recovery last week. ASCO presentations dominated the headlines, with Iovance Biotherapeutics Inc (NASDAQ: IOVA ) and Mirati Therapeutics Inc (NASDAQ: MRTX ) among the biggest ...

  • Alnylam Completes Rolling NDA Submission to FDA for Givosiran
    Zacks19 days ago

    Alnylam Completes Rolling NDA Submission to FDA for Givosiran

    Alnylam (ALNY) completes the rolling NDA submission to the FDA for givosiran, which is being evaluated for the treatment of acute hepatic porphyria.